Immunotherapy

Oregon Health & Science University has implemented a “symptom science” clinical research program designed to mitigate toxicities and improve quality of life for people with cancer.

The ADAPT OIT program builds peanut tolerance in babies with daily dosing of peanut powder administered by caregivers at home, according to a National Allergy Centre of Excellence and Murdoch Children’s Research Institute press release.

DBV Technologies recently provided updates on its Viaskin Peanut Program for children and toddlers, announcing recruitment for the VITESSE study and progress in the COMFORT Toddlers supplemental safety study.

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.

Combining gut microbiome manipulation with immunotherapy and tyrosine kinase inhibitor therapy conveyed clinical benefit for patients with metastatic renal cell carcinoma, results of a randomized phase 1 trial showed.

Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia increasingly receive tisagenlecleucel in earlier settings when they have lower disease burden, according to findings presented at ASCO Annual Meeting.

The FDA has approved Palforzia, an oral immunotherapy designed to protect children aged 1 to 3 years with peanut allergies from reactions caused by accidental exposure, according to a press release.

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

The addition of a pre-ketone supplement to an immunotherapy regimen demonstrated efficacy for treating prostate cancer, according to a study led by researchers at University of Notre Dame.